The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% ...

Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to ...

Shares of Swedish pharma firm Orexo leapt 20.2% to 20.60 kronor this morning, following its announcement over the weekend ...

BioNTech resumes its PRESERVE-003 trial for gotistobart as a monotherapy in metastatic squamous NSCLC after a partial ...

UK-based Puretech Health has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at ...

VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...

The buy will bolster Pharming’s pipeline with Abliva’s lead asset, KL1333, a promising therapy for mitochondrial disease.

US biotech Checkpoint Therapeutics saw its shares jump more than 16% to $4.27 in after-hours trading on Friday, on the news ...

At the request of the individual product sponsors, the US Food and Drug Administration (FDA) has revoked the Emergency Use ...

UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael ...

Relation’s 'Lab-in-the-Loop' platform combines human genetics, single-cell multi-omics directly from human tissue, functional ...

Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday.